Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Todd Neale

October 03, 2019

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Gennaro Giustino

October 30, 2017

Presentation TCT 2017

Strengths and Limitations of Composite Endpoints (eg, EXCEL, PLATO, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Stuart J. Pocock

October 30, 2017

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Conference News TCT 2014

PLATO Subanalysis: Ticagrelor Safe, Effective in Primary PCI

September 15, 2014

Presentation TCT 2014

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Philippe Gabriel Steg

September 14, 2014

Presentation TCT 2013

Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial

Presenter: Emmanouil Brilakis, Claes Held, Bernhard Meier, Frank Cools, Marc Claeys, Jan Cornel, Philip Aylward, Basil Lewis, Douglas Weaver, Gunnar Brandrup- Wognsen, Susanna Stevens, Lars Wallentin, Stefan James

January 31, 2013

Presentation TCT 2012

Ticagrelor Update: PLATO: Recent Analyses

Presenter: Robert Harrington

October 24, 2012

News Conference News

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

November 08, 2011

News Conference News

Prasugrel, Ticagrelor Reduced Incidence of Stent Thrombosis

November 06, 2011

Advertisement

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Strengths and Limitations of Composite Endpoints (eg, EXCEL, PLATO, and Others)

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

PLATO Subanalysis: Ticagrelor Safe, Effective in Primary PCI

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial

Ticagrelor Update: PLATO: Recent Analyses

Mock Jury Votes on DAPT Duration: 12 Months Remains Best Option for Most Patients

Prasugrel, Ticagrelor Reduced Incidence of Stent Thrombosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content